ECE2011 Poster Presentations Clinical case reports (73 abstracts)
MGMT immunoexpression in adamantinomatous craniopharyngiomas
Sayid Shafi Zuhur 1 , Ahmet Murat Musluman 2 , Canan Tanik 3 , Ozcan Karaman 1 , Feyza Yener Ozturk 1 , Hanife Ozkayalar 3 & Yuksel Altuntas 1
1Sisli Etfal Training and Research Hospital, Endocrinology and Metabolism Department, Istanbul, Turkey; 2Sisli Etfal Training and Research Hospital, Neurosurgery Department, Istanbul, Turkey; 3Sisli Etfal Training and Research Hospital, Pathology Department, Istanbul, Turkey.
Background: Currently, no effective medical treatment exists for recurrent and aggressive craniopharyngiomas that are resistant to conventional therapies, including repeat surgeries and adjuvant radiotherapy (RT). Temozolomide is an alkylating chemotherapeutic agent and is used routinely in the management of high grade gliomas. The response to temozolomide is suggested to be dependent on the tumoral expression of O-6 methylguanine DNA methyltransferase (MGMT). Evidence supports that low MGMT immunoexpression correlates with positive response to temozolomide
Purpose: We aimed to evaluate MGMT immunoexpression in adamantinomatous craniopharyngiomas, in an effort to predict the likelihood of response to temozolomide.
Methods: Our material consisted of 23 adamantinomatous craniofaryngiomas operated at the Sisli Etfal Training and Research Hospital during the interval 1993–2009 and identified by histological analysis. Immunostaining for MGMT was performed using the avidin–biotin–peroxidase complex method. MGMT immunoreactivity was evaluated microscopically and recorded as percentage of nuclear MGMT immunostaining.
Results: Of the 23 specimens evaluated, 22 (96%) demonstrated negative (<10%) and 1 (4%) demonstrated low (10%) MGMT immunoexpression.
Conclusion: The data provided by the current study suggests all adamantinomatous craniopharyngiomas exhibit low MGMT immunoreactivity and could be treated with temozolomide. Our findings provide a ground for the assessment of TMZ’s efficacy in clinical trials as an alternative agent in this rare tumor subtype, if conventional therapy, including repeat surgeries and RT, fails.
Volume 26
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more